(IPSC) Century Therapeutics, Inc. Business Model Canvas Research

Century Therapeutics, Inc. relies on research and translational collaborators to speed iPSC biology, CAR engineering, and solid-tumor target validation. These partners help stress-test targets such as CD19, CD133, EGFR, CD79b, AML, and myeloma markers, making collaborative science a direct input to pipeline growth.

• Validates high-value targets
• Supports CAR design and testing
• Expands blood and solid-tumor pipeline

That external science matters because Century Therapeutics, Inc. uses partner data to reduce target risk before pushing programs deeper into development.

Century Therapeutics, Inc. depends on suppliers of reagents, vectors, antibodies, media, and lab consumables because these inputs keep cell therapy R&D and GMP manufacturing consistent from preclinical work through clinical batches. In its latest public filings, Century Therapeutics, Inc. does not disclose a single critical supplier, so stable multi-source procurement matters for quality and continuity.

• Specialized inputs drive process consistency.
• Supplier quality affects batch reproducibility.
• Supply stability supports clinical scale-up.

Century Therapeutics, Inc. must keep manufacturing process development tight so its allogeneic cell therapies can scale from lab runs to commercial batches, with process optimization, comparability, and release specs all locked down. Manufacturing robustness is the gatekeeper here: without reproducible lots and low batch failure risk, even a pre-commercial cell therapy platform cannot support durable economics.

• Scale allogeneic production
• Prove comparability between batches
• Tighten release specifications
• Reduce batch risk and cost

Century Therapeutics’ regulatory and quality work centers on keeping INDs current, meeting FDA and other agency rules, and proving safety and manufacturing control across its cell-therapy pipeline. This is critical because the FDA approved 55 novel drugs in 2025, so trial discipline and clean quality records can directly affect approval odds.

• Maintain INDs and trial filings
• Track safety and CMC controls
• Manage regulator interactions
• Support trials and approvals

Century Therapeutics, Inc. depends on scientific and technical talent in cell engineering, immunology, translational medicine, and clinical ops to turn platform science into drug candidates and trial-ready products. In early-stage biotech, human capital is the core asset; without these teams, platform IP cannot move into IND-enabling work or clinical testing.

It is a people-heavy model, where execution speed and scientific depth drive value.

• Cell engineering converts platforms into products.
• Immunology guides target and safety choices.
• Clinical ops moves candidates into trials.

Century Therapeutics, Inc. is headquartered in Philadelphia, Pennsylvania, where management, research coordination, and corporate functions are based. A single operating base supports tighter oversight of its complex cell therapy platform and keeps decision-making close to the core team.

• Philadelphia, Pennsylvania headquarters
• Centralizes management and research coordination
• Supports one operating base for oversight

Century Therapeutics’ value lies in one platform with 2 cell formats: CAR-iNK and CAR-iT. That lets the Company match cell type to disease biology and treatment need, which can widen both clinical reach and future commercial use across blood cancers and solid tumors.

• 2 modalities: CAR-iNK and CAR-iT
• Fits biology to the target disease
• Broadens clinical and commercial reach

Century Therapeutics, Inc. targets refractory cancers where treatment choices are few, led by relapsed or refractory B-cell lymphoma, a market with high unmet need and roughly 1,600 U.S. diffuse large B-cell lymphoma deaths each year among the hardest-to-treat cases. Its pipeline also reaches recurrent glioblastoma, AML, and multiple myeloma, so the value is tied to patients who need new options after standard care fails.

• Focuses on hard-to-treat, post-relapse patients
• Lead asset targets B-cell lymphoma
• Also covers glioblastoma, AML, myeloma

Century Therapeutics, Inc. needs patient-focused trial support because cell therapy studies often require 4+ site touchpoints, from education and apheresis to infusion and follow-up. Clear navigation, logistics help, and scheduled check-ins through the study site can reduce drop-off and improve retention in oncology trials, where every missed visit can slow data readout.

• Complex pathways need hands-on guidance
• Site-coordinated follow-up supports retention
• Fewer missed visits protect trial data

Century Therapeutics, Inc. must keep investors and strategic partners updated on clinical milestones, manufacturing readouts, and financing needs so they can track execution and risk. Clear, timely communication helps support capital access and deal talks, especially as the company advances cell therapy programs through costly development steps.

• Update pipeline milestones fast
• Share manufacturing progress clearly
• Explain financing runway and needs
• Support funding and partnerships

Peer-reviewed publications are a key channel for Century Therapeutics, Inc. because they turn preclinical and clinical data into third-party validated evidence, which helps prove platform differentiation and build trust with scientists, clinicians, and partners. In biotech, published results often reach a wider evidence-based audience than direct sales outreach, so they support credibility and deal flow.

• Validate preclinical and clinical claims
• Differentiate the cell therapy platform
• Support evidence-based partner engagement

Century Therapeutics, Inc. uses its investor relations channel to keep shareholders and analysts updated on pipeline progress, financing, and governance. Its corporate website is the main source for SEC filings, board details, and company news, which helps drive visibility and support capital access.

• Reaches shareholders and analysts
• Shares pipeline and governance updates
• Supports financing and market visibility

CNTY-104 and CNTY-106 target AML and multiple myeloma, two high-relapse blood cancer markets with large unmet need. In the U.S., AML is about 20,000 new cases a year, while multiple myeloma is about 36,000, so Century Therapeutics, Inc. can reach a broad pool of patients who often need repeat lines of therapy.

• Large hematologic oncology addressable markets
• High relapse risk drives repeat demand
• Broader patient base for CNTY-104 and CNTY-106

Oncology treatment centers are the main institutional buyers for Century Therapeutics, Inc. They do the infusion work, so the product has to be easy to handle, backed by training, and supplied on time. This matters because cell therapy is still concentrated in specialized centers, and access to the patient starts with the hospital’s ability to deliver the treatment.

In Century Therapeutics, Inc.'s latest reporting cycle, the company remained in the clinical stage with no commercial product revenue, so winning center adoption is a key step before scale. For these buyers, reliable manufacturing, clear protocols, and low site burden are as important as efficacy data.

• Specialized hospitals drive patient access.
• Sites need simple handling and training.
• Supply reliability affects treatment flow.

Regulatory and quality systems are a fixed cost in Century Therapeutics, Inc.'s cell therapy model: every clinical batch needs documentation, QA release, audits, and validation before dosing. These costs rise with each program and site, so compliance is not optional overhead but a core gate to clinical development.

• QA staff and audit work are required
• Batch records and validation add fixed cost
• Regulatory readiness is always on

Century Therapeutics, Inc. carries general and administrative overhead for public-company functions: corporate, legal, finance, and investor relations. Its Philadelphia headquarters also adds occupancy and admin spend, supporting the operating platform and day-to-day compliance, reporting, and stakeholder outreach.

• Public-company compliance and reporting
• Legal, finance, and IR teams
• Philadelphia HQ occupancy and admin costs

Century Therapeutics, Inc. can earn research collaboration payments from partners to fund target discovery, preclinical studies, and shared development work. This revenue is usually early-stage and non-recurring, so it can vary a lot by program and milestone timing.

• Partner-funded, milestone-driven cash
• Supports discovery and preclinical work
• Usually not recurring revenue

Century Therapeutics, Inc. can use grants and other non-dilutive funding to support platform science and translational work without waiting for product sales or issuing new shares. U.S. NIH grant funding totaled about $36.2 billion in FY2024, showing how early biotech R&D can tap public capital to reduce cash burn.

• Funds R&D without dilution
• Supports preclinical platform work
• Bridges to translational milestones
• Limits dependence on sales timing